Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) announced better-than-expected revenue in Q1 CY2026, with sales up 19.1% year on year to $1.07 billion. On the other hand, the company’s full-year revenue guidance of $4.38 billion at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP profit of $6.34 per share was 36.2% above analysts’ consensus estimates.

Is now the time to buy Jazz Pharmaceuticals? Find out by accessing our full research report, it’s free.

"Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

Company Overview

Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.

Revenue Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Thankfully, Jazz Pharmaceuticals’s 11.7% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Jazz Pharmaceuticals’s recent performance shows its demand has slowed as its annualized revenue growth of 7.5% over the last two years was below its five-year trend. We’re wary when companies in the sector see decelerations in revenue growth, as it could signal changing consumer tastes aided by low switching costs.

This quarter, Jazz Pharmaceuticals reported year-on-year revenue growth of 19.1%, and its $1.07 billion of revenue exceeded Wall Street’s estimates by 9.4%.

Looking ahead, sell-side analysts expect revenue to decline by 4.4% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and suggests its products and services will face some demand challenges.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Adjusted Operating Margin

Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes.

Jazz Pharmaceuticals has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 34.9%.

Analyzing the trend in its profitability, Jazz Pharmaceuticals’s adjusted operating margin decreased by 25.1 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 22.1 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

In Q1, Jazz Pharmaceuticals generated an adjusted operating margin profit margin of 31.5%, up 9.7 percentage points year on year. This increase was a welcome development and shows it was more efficient.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Sadly for Jazz Pharmaceuticals, its EPS declined by 4.2% annually over the last five years while its revenue grew by 11.7%. This tells us the company became less profitable on a per-share basis as it expanded.

We can take a deeper look into Jazz Pharmaceuticals’s earnings to better understand the drivers of its performance. As we mentioned earlier, Jazz Pharmaceuticals’s adjusted operating margin expanded this quarter but declined by 25.1 percentage points over the last five years. Its share count also grew by 13.2%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders.

In Q1, Jazz Pharmaceuticals reported adjusted EPS of $6.34, up from $1.68 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. We also like to analyze expected EPS growth based on Wall Street analysts’ consensus projections, but there is insufficient data.

Key Takeaways from Jazz Pharmaceuticals’s Q1 Results

It was good to see Jazz Pharmaceuticals beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. On the other hand, its full-year revenue guidance missed. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 2.8% to $218.30 immediately following the results.

Indeed, Jazz Pharmaceuticals had a rock-solid quarterly earnings result, but is this stock a good investment here? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).